Macrocycle Therapeutics to Treat Life-threatening Diseases

被引：3
|
作者：
Batur, Gokhan [1 ]
Ermert, Philipp [1 ]
Zimmermann, Johann [1 ]
Obrecht, Daniel [1 ]
机构：
[1] Polyphor Ltd, Hegenheimermattweg 125, CH-4123 Allschwil, Switzerland
来源：
CHIMIA | 2021年 / 75卷 / 06期
关键词：
Antibiotic; Breast cancer; CXCR4; inhibitor; Macrocycle; Protein epitope mimetic; SYNTHETIC PEPTIDE; CXCR4; POTENT; CHEMOTHERAPY; MOBILIZATION; METASTASIS; ANTAGONIST; INHIBITOR; DISCOVERY; THANATIN;
D O I：
10.2533/chimia.2021.508
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Polyphor's macrocycle platform led to the discovery of novel antibiotics addressing specifically Gramnegative bacteria by targeting outer membrane proteins. Furthermore, POL6014, an inhibitor of neutrophile elastase and balixafortide, a CXCR4 inhibitor have been discovered and developed from the platform. Currently a combination of balixafortide and eribulin is in Phase III clinical trial for the treatment of patients with advanced metastatic HER2-negative breast cancer.
引用
收藏
页码：508 / 513
页数：6
相关论文
共 50 条
12345